P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential by Weisman, Gary A. et al.
P2Y Receptors in the Mammalian Nervous System: 
Pharmacology, Ligands and Therapeutic Potential
Gary A. Weisman*,1,2,3, Lucas T. Woods1,3, Laurie Erb1,3, and Cheikh I. Seye4
1Department of Biochemistry, University of Missouri, Columbia, Missouri, USA
2Interdisciplinary Neuroscience Program, University of Missouri, Columbia, Missouri, USA
3Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA
4Department of Cellular and Integrative Physiology, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
Abstract
P2Y receptors for extracellular nucleotides are coupled to activation of a variety of G proteins and 
stimulate diverse intracellular signaling pathways that regulate functions of cell types that 
comprise the central nervous system (CNS). There are 8 different subtypes of P2Y receptor 
expressed in cells of the CNS that are activated by a select group of nucleotide agonists. Here, the 
agonist selectivity of these 8 P2Y receptor subtypes is reviewed with an emphasis on synthetic 
agonists with high potency and resistance to degradation by extracellular nucleotidases that have 
potential applications as therapeutic agents. In addition, the recent identification of a wide variety 
of subtype-selective antagonists is discussed, since these compounds are critical for discerning 
cellular responses mediated by activation of individual P2Y receptor subtypes. The functional 
expression of P2Y receptor subtypes in cells that comprise the CNS is also reviewed and the role 
of each subtype in the regulation of physiological and pathophysiological responses is considered. 
Other topics include the role of P2Y receptors in the regulation of blood-brain barrier integrity and 
potential interactions between different P2Y receptor subtypes that likely impact tissue responses 
to extracellular nucleotides in the CNS. Overall, current research suggests that P2Y receptors in 
the CNS regulate repair mechanisms that are triggered by tissue damage, inflammation and 
disease and thus P2Y receptors represent promising targets for the treatment of neurodegenerative 
diseases.
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INTRODUCTION
P2 receptors are a diverse group of cell surface nucleotide receptors that can be separated 
into two structurally distinct subtypes: the P2X receptors that are ligand-gated ion channels 
and the G protein-coupled P2Y receptors. Genes for seven P2X receptor subtypes (i.e., 
P2X1-7) have been characterized and their physiological function and therapeutic relevance 
are discussed in other chapters in this issue. P2Y receptors are seven transmembrane 
spanning proteins that bind extracellular nucleotides to cause the activation of heterotrimeric 
G proteins and the transduction of intracellular signaling pathways that regulate a wide 
variety of cellular responses. To date, eight different subtypes of P2Y receptors have been 
cloned and characterized in mammalian cells of multiple species and have been shown to be 
activated by structurally distinct nucleotide agonists, including adenosine 5’-triphosphate 
(ATP), adenosine 5’-diphosphate (ADP), uridine 5’-triphosphate (UTP), uridine 5’-
diphosphate (UDP) and UDP-glucose [1-3], as described in Table 1. Endogenous P2Y 
receptor (P2YR) agonists are released from cells in the central nervous system (CNS) under 
various conditions, including exocytosis at nerve terminals [4, 5], the opening of pannexin 1 
hemi-channels [6-9], oxygen deprivation and apoptosis [4, 6], whereupon they activate all 8 
subtypes of P2Y receptors (i.e., P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14) that are expressed in 
cells that comprise the CNS (e.g., neurons, astrocytes, microglia and endothelial cells) [3, 
10-19]. This review will describe the signaling pathways coupled to activation of each 
P2YR subtype and the physiological and pathophysiological responses regulated by P2YRs 
in the CNS. For example, P2YRs have been shown to regulate neurotransmission, cell 
growth, inflammatory responses and apoptosis [10-13, 20-23]. Recent studies have provided 
evidence that activation of P2YRs has both neuroprotective and neurodegenerative 
consequences in the CNS [24, 25] and, therefore, P2YRs represent novel therapeutic targets 
for the treatment of neurodegenerative diseases, as will be described for each P2YR subtype. 
In addition, we will summarize the current state of P2YR subtype-selective agonists and 
antagonists that could potentially represent promising drugs for modulation of cellular 
functions in the CNS.
COMMON STRUCTURAL AND SIGNALING FEATURES OF P2Y 
RECEPTORS
The primary and secondary structures of P2YRs indicate the presence of an extracellular N-
terminus followed by seven transmembrane spanning domains that delineate 3 extracellular 
loops and 3 intracellular loops and an intracellular C-terminal tail that varies significantly 
among the P2YR subtypes [3, 26-29]. The number of amino acids in human P2YR subtypes 
ranges from 328 (for P2Y6R) to 377 (for P2Y2R) and these subtypes have ~20 to 50% 
homology [30]. Binding of the negatively charged P2YR agonists within the transmembrane 
domain is likely facilitated by several positively charged amino acids that are conserved 
among the P2YR subtypes [27, 31, 32] and information from site-directed mutagenesis 
experiments has suggested a model of the ligand-binding site for some subtypes [33, 34]. 
Once activated by nucleotide agonists, P2YRs stimulate GDP-GTP exchange by 
heterotrimeric G proteins whereupon dissociation of the GTP-Gα subunit modulates the 
activities of intracellular enzymes, including phospholipase C and adenylyl cyclase, to 
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activate intracellular signaling cascades that regulate multiple cell type-specific responses 
[3, 35]. Among the P2YR subtypes, the P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptors are 
coupled to Gq protein and the activation of phospholipase C which promotes the hydrolysis 
of the plasma membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) to 
generate two second messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol that 
induce release of Ca2+ from intracellular stores and activate protein kinase C (PKC), 
respectively [3, 36]. Alternatively, P2Y12, P2Y13 and P2Y14 receptors are coupled to Gi/o 
proteins which regulate the activity of adenylyl cyclase and production of the downstream 
effector cyclic adenosine 5’-monophosphate (cAMP) [3, 36]. P2YRs have also been shown 
to activate additional subfamilies of G proteins either directly or indirectly through 
interactions with other plasma membrane receptors, as described below.
P2YRs, like most G protein-coupled receptors, are desensitized by prolonged agonist 
treatment due to phosphorylation of intracellular sites in the receptor that promotes the 
binding of β-arrestins and subsequent receptor internalization and/or degradation [37]. β-
Arrestins can regulate receptor desensitization by interfering with G protein coupling and 
interacting with clathrin and AP2 to induce endocytosis [37]. Most P2YRs interact with β-
arrestin-2, although the P2Y2 and P2Y4 receptors also interact with β-arrestin 1 [38]. 
Receptor endocytosis regulated by β-arrestins has been shown to activate intracellular 
mitogen-activated protein kinases [37], such as ERK1/2, a target of many P2YR signaling 
cascades, and differential coupling of P2YRs to β-arrestins may explain variations in 
ERK1/2 activation induced by different P2YR agonists [38]. Agonist-induced 
desensitization of most P2YRs, except for the P2Y2R, also is dependent on the protein 
dynamin [38].
P2Y RECEPTOR SUBTYPES
The P2Y1 Receptor
The P2Y1R is activated by the endogenous agonist ADP (EC50 = 10 nM) and is directly 
coupled to activation of Gq proteins [39]. When the human P2Y1R was overexpressed in Sf9 
insect cells, then purified and reconstituted in proteoliposomes along with heterotrimeric G 
proteins, it was demonstrated that receptor activation was also coupled to activation of Gα11 
proteins (determined by increases in 2-methylthio-ADP-induced GTP hydrolysis) whose 
activity was enhanced by the presence of the GTPase-activating proteins RGS4 and PLCβ1 
[40]. The synthetic agonist 2-methylthio-ADP (2-MeS-ADP; EC50 = 2 nM) has been widely 
used to induce P2Y1R activation, although it can also activate the P2Y12 and P2Y13 
receptors [41]. The 2-MeS-ADP analog (N)-methanocarba-2-methylthio-ADP (MRS2365) 
was found to be a highly potent and stable agonist at the human P2Y1R with an EC50 = 0.4 
nM [42]. Other studies have synthesized derivatives of adenosine 5'-O-(1-
boranotriphosphate) (ATP-α-B) and β,γ-methyl-ATP that are P2Y1R agonists and are 
relatively insensitive to hydrolysis by nucleoside 5’-triphosphate diphosphohydrolase 
(NTPDase), as compared to endogenous agonists, suggesting their potential as therapeutic 
agonists with long-term stability [43, 44]. Similarly, dinucleoside polyphosphate derivatives 
including diadenosine (γ-borano)pentaphosphate (Ap5(γ-B)A) have proven to be potent and 
selective P2Y1R agonists [45, 46]. Di-(2-MeS)-adenosine 5',5"-P1,P4,α,β-methylene-
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tetraphosphate and 2-MeS-β,γ-CCl2-ATP also have been shown to be stable P2Y1R agonists 
with potential for the treatment of human disease due to their ability to stimulate insulin 
secretion in rats and relieve intraocular pressure in rabbits, respectively [47, 48].
P2Y1R activation has been shown to be antagonized by the ATP analogs, ATPaS and β,γ-
methylene-ATP, which act as competitive antagonists, whereas pyridoxal-phosphate-6-
azophenyl-2',4'-disulphonic acid (PPADS) and suramin were also shown to inhibit P2Y1R 
activity [49], although these latter compounds are not selective for the P2Y1R [50]. 
Adenosine-3'-phosphate-5'-phosphosulfate (A3P5PS), adenosine-3'-phosphate-5'-phosphate 
(A3P5P), adenosine-2'-phosphate-5'-phosphate (A2P5P) and adenosine-2',5'-diphosphate are 
competitive antagonists at the turkey and human P2Y1Rs and A3P5PS and A3P5P were 
devoid of agonist or antagonist activities at the P2Y2, P2Y4 and P2Y6 receptors [51, 52]. 
These initial observations describing P2Y1R antagonism by bisphosphates (i.e., A3P5P) led 
to the development of synthetic analogs such as N6-methyl 2'-deoxyadenosine 3',5'-
bisphosphate (N6MABP; or MRS2179) which also antagonizes the P2Y1R without effects 
on the human P2Y2, P2Y4 and P2Y6 receptors [53, 54]. Additional synthetic bisphosphate 
antagonists of the P2Y1R include 2-iodo-N(6)-methyl-(N)-methanocarba-2'-
deoxyadenosine-3',5'-bisphosphate (MRS2500), which was shown to be a potent and 
selective P2Y1R antagonist [55, 56], and 2-chloro N(6)-methyl-(N)-methanocarba-2'-
deoxyadenosine-3',5'-bisphosphate (MRS2279), which was shown to be a selective 
competitive P2Y1R antagonist without an effect on P2Y2, P2Y4, P2Y6, P2Y11 and P2Y12 
receptors [57]. Other studies have indicated that, whereas N6-methyl modification enhances 
the antagonist potency of 2'-deoxyadenosine 3',5'-bisphosphate at the P2Y1R, this effect is 
inhibited by benzoylation or dimethylation of the N6-amino group of adenosine or by its 
replacement with methylthio, chloro, or hydroxy groups [58].
The P2Y1R is widely expressed in the mammalian brain, including in the cerebral cortex, 
hippocampus, caudate nucleus, putamen, globus pallidus, habenula, subthalamic nucleus, 
midbrain and cerebellum [59-61]. The P2Y1R is expressed in Purkinje cells in the 
cerebellum, in regions of the cerebral cortex, in ischemia-sensitive areas of the hippocampus 
[61] and in oligodendrocytes and astrocytes in brain and optic nerves [14, 59]. P2Y1Rs also 
have been shown to regulate glial cell functions [61]. In hippocampal astrocytes, P2Y1R 
activation has been suggested to provide neuroprotection from oxidative stress via increased 
interleukin-6 (IL-6) release [62] and to play roles in brain development and repair [63] and 
sensory reception [64, 65]. Other studies indicate that P2Y1Rs also are expressed in 
microglial cells [59, 66], rat neuroprogenitor cells [63], and dorsal root ganglia and horn 
neurons [65, 67, 68]. Furthermore, recent studies with P2Y1R knockout mice indicate that 
P2Y1Rs mediate neurotransmission in the gastrointestinal tract [69].
Consistent with studies indicating the role of the P2Y1 receptor in increasing cytokine (i.e., 
IL-6) release [62], intracerebroventricular administration of the P2Y1R antagonist, 
MRS2179, significantly decreased the expression of IL-6, phospho-RelA (p-RelA), tumor 
necrosis factor-α, monocyte chemotactic protein-1/chemokine (C-C motif) ligand 2 (CCL2), 
and interferon-inducible protein-10/chemokine (C-X-C motif) ligand 10 (CXCL10) mRNA 
in a rat model of cerebral ischemia/reperfusion [25]. While previous studies indicated that 
P2Y1R-induced IL-6 release provided neuroprotection [62], intracerebroventricular 
Weisman et al. Page 4
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2015 March 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
administration of the P2Y1R agonist MRS2365 was shown to increase cerebral infarct 
volume due to cerebral ischemia/reperfusion, whereas administration of the P2Y1R 
antagonist MRS2179 decreased infarct volume [25]. Additionally, P2Y1R and p-RelA 
colocalized with glial fibrillary acidic protein-positive astrocytes, suggesting that P2Y1R 
expression in cortical astrocytes mediates cytokine/chemokine-induced damage that occurs 
during cerebral ischemia/reperfusion, which can be prevented by antagonists of the P2Y1R 
[25]. The effects of P2Y1R agonism/antagonism appear to be experimental model-dependent 
making it difficult to determine the potential therapeutic role in treatment of ischemia-
related damage. In brain sections from Alzheimer’s disease (AD) patients, P2Y1Rs in 
neurons have been shown to colocalize with neurofibrillary tangles and neuritic plaques, as 
compared to samples from control patients [70]. While the significance of these observations 
is unclear, P2Y1R-mediated stimulation of Gq protein has been shown to activate the small 
GTPase cytoskeletal modulator Rac [71], which recent studies have shown enhances axonal 
elongation [72], although this effect was shown to occur through a mechanism involving 
adenylate cyclase 5 and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Nonetheless, 
these data suggest that the P2Y1R may play a neuroprotective role in AD by promoting 
axonal elongation to counteract the neurotoxic effects of neurofibrillary tangles. While 
further research is needed to validate this speculative therapeutic pathway, it stands to 
reason that selective P2Y1R agonists and antagonists should be investigated for therapeutic 
utility in the modulation of neurodegenerative disease phenotypes, such as AD, amyotrophic 
lateral sclerosis (ALS) and Parkinson’s disease.
P2Y1R activation also has been shown to cause PKC-dependent phosphorylation of the 
capsaicin receptor (a VR1 cation channel) that can alter the perception of pain [73]. The 
potential therapeutic use of P2Y1R antagonists in pain perception is highlighted by a recent 
study showing significantly decreased tactile allodynia in a rat model of bone pain following 
treatment with the P2Y1R antagonist MRS2179 [74]. Additionally, intracerebroventricular 
injection of the P2Y1R agonist ADPβS was shown to increase anxiolytic-like behavior in a 
rat model of anxiety [75]. Furthermore, this behavior was attenuated by injection of the 
P2Y1R antagonist MRS2179, suggesting another possible therapeutic pathway that may be 
exploited using specific P2Y1R antagonists.
The P2Y2 Receptor
The P2Y2R is activated equipotently by the fully ionized forms of ATP or UTP (i.e., by 
NTP4−) with an EC50 ~ 0.5-3 µM [76-79], suggesting that this P2YR subtype is primarily 
activated in close proximity to released nucleotides or under conditions associated with high 
levels of extracellular ATP and UTP (e.g., inflammation and apoptosis). It seems likely that 
the negatively-charged triphosphate moieties of these structurally distinct purine (i.e., ATP) 
and pyrimidine (i.e., UTP) nucleotides promote agonist binding to the P2Y2R, since 
selective deletion of positively charged amino acids in the 6th and 7th transmembrane 
domains inhibits P2Y2R activity [27]. Uridine-5'-O-(3-thio)triphosphate (UTPyS) has been 
shown to be equally potent to UTP as a P2Y2R agonist and relatively resistant to hydrolysis 
by alkaline or acid phosphatase and apyrase [78]. Diadenosine tetraphosphate (Ap4A) 
displays relatively potent (EC50 = 720 nM) agonist activity at the P2Y2R and has been 
suggested to be an endogenous agonist [80]. The observation that dinucleoside 
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polyphosphates have agonist activity at P2Y receptors led to pharmacological investigations 
of similar compounds, such as P1,P4-di(uridine-5’-) tetraphosphate (Up4U; INS365; 
Diquafosol), which was shown to be a potent agonist of the P2Y2R (EC50 = 100 nM) and 
also displayed agonist activity at the P2Y4R and the P2Y6R [81]. Similarly, P1-(inosine 
5’-)P4-(uridine 5’-) tetraphosphate (Ip4U; INS45973), which has EC50 values for the P2Y2R 
and the P2Y4R of ~ 280 nM and an EC50 for the P2Y6R of >10 µM, has been used 
intravenously in mice to demonstrate that activation of the P2Y2R decreases blood pressure 
and increases renal Na+ excretion [82]. The relative potency and selectivity of these 
compounds along with the development of the more hydrolytically stable P2Y2R agonist 
P(1)-(uridine 5')-P(4)-(2'-deoxycytidine 5')-tetraphosphate (dCp4U; INS37217; Denusofol) 
[83, 84] led to several clinical investigations into the therapeutic potential of these P2Y2R 
agonists to increase fluid flow across epithelial cell membranes that has been shown to be 
regulated by the P2Y2R [85-88]. However, recent Phase III clinical trials for INS37217 in 
the treatment of cystic fibrosis and INS365 in the treatment of dry eye, two epithelial-based 
diseases with underlying defects in fluid flow, failed to achieve their primary endpoints. 
Other documented P2Y2R agonists include 2'-amino-2'-deoxy-UTP, 6-nitro-UTP, UTPaS 
and 2'-deoxy-UTPaS [89], 2-thio-UTP [90], uridine-5'-tetraphosphate 8-phenyl ester 
(MRS2768), dihalomethylene phosphonate analogues and the 2-thio analogue of INS37217 
[91]. A recently developed P2Y2R agonist, 4-thiouridine-5'-O-(β,γ-difluoromethylene) 
triphosphate (PSB1114), shows 60-fold increased selectivity at the P2Y2R, as compared to 
the P2Y4R or the P2Y6R [92], which potentially provides an agent for selective in vivo 
activation of the P2Y2R among the known uridine nucleotide receptor subtypes.
P2Y2R activation mediates Gq-dependent stimulation of phospholipase C (PLC), although 
the P2Y2R has been shown to induce GTPy[35S] incorporation into Gq, Go and G12 proteins 
[93-94]. Only Gq appears to be directly coupled to P2Y2R activation, since activation of Go 
and G12 proteins was shown to require the presence of the consensus integrin-binding 
arginine-glycine-aspartic acid (RGD) motif in the first extracellular loop of the P2Y2R 
whose deletion prevents receptor interaction with αv integrins and the activation Go and G12, 
but not Gq proteins [93-95]. Although activation of PLC by the P2Y2R has been shown to 
require GTP binding to Gαq11 [96], the P2Y2R also has been found to modulate 
phospholipase C activities via Gαq16 [97] and Gβγi3 [96].
There have been few P2Y2R-selective antagonists described, although PPADS and suramin 
are non-selective P2Y2R antagonists [98, 99]. The non-nucleotide compound 1-amino-4-(2-
methoxyphenyl)-2-sulfoanthraquinone (PSB716) has been shown to be a potent P2Y2R 
antagonist with an IC50 value in the low micromolar range [100]. To date, the most reliable 
means of inhibiting P2Y2R function has been the use of P2Y2R-selective antisense 
oligonucleo-tides or siRNA or deletion of the P2Y2R in transgenic mice [24, 101, 102]. 
Accordingly, there is a critical need for the development of P2Y2R-selective antagonists and 
agonists, particularly those that can cross the blood-brain barrier, since this P2YR subtype 
represents a promising target in the treatment of neuroinflammatory and neurodegenerative 
diseases, such as Alzheimer’s disease, as described below.
The P2Y2R subtype likely plays a role in CNS functions predominantly under 
pathophysiological conditions, including inflammation and bacterial infection [103-106]. 
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The P2Y2R has been found to be upregulated in cell and animal models under a variety of 
conditions associated with inflammation or injury [16, 107-111], including spinal cord 
injury [112] and brain trauma [113], which suggests the possibility that the P2Y2R plays a 
protective role in the CNS. P2Y2R expression is upregulated by treatment of rat primary 
cortical neurons with the proinflammatory cytokine interleukin-1β (IL-1β) [16], and levels of 
IL-1β have been shown to be elevated in the brains of AD patients, as compared to normal 
controls [114, 115]. Consistent with a role in inflammation, P2Y2R expression under 
proinflammatory conditions has been shown to require binding to the P2Y2R promoter of 
NF-κB [116], a transcription factor known to regulate gene expression in inflammation 
[117].
P2Y2R activation has been shown to increase the migration and proliferation of astrocytic 
and microglial cells [24, 93, 118-120]. The mechanism of P2Y2R-mediated cell migration 
appears to require more than Gq-coupled activation of PLC, since cytoskeletal 
rearrangements and cell migration induced by the P2Y2R agonist UTP were abolished in 
astrocytoma cells that express a mutant P2Y2R in which aspartic acid in a consensus 
integrin-binding RGD motif was modified to glutamic acid to generate RGE, which prevents 
the P2Y2R from binding to αv integrins [93-94]. This result suggests a requirement for 
P2Y2R interaction with αv integrins to mediate UTP-induced cell migration. Consistent with 
this conclusion, UTP-induced Go-dependent Rac1 and G12-dependent RhoA activation, 
pathways well known to regulate actin polymerization and depolymerization required for 
cell migration [121, 122], were absent in cells expressing the RGE-mutant of the P2Y2R 
[93-95]. Other data suggest that increases in cell proliferation caused by P2Y2R activation 
are due to the ability of the P2Y2R to induce phosphorylation and activation of growth 
factor receptors that leads to increases in the activities of the mitogen-activated protein 
kinases ERK1/2 and the related adhesion focal tyrosine kinase (RAFTK; Pyk 2) via a 
pathway dependent upon Src and Shc/Grb2 [123-125]. The P2Y2R contains Src-homology-3 
(SH3) binding motifs in the intracellular C-terminal domain that when deleted can prevent 
growth factor receptor activation [125, 126], suggesting that agonist-induced Src binding to 
these SH3-binding sites can regulate P2Y2R-mediated cell proliferation. Other studies 
indicate that the C-terminal domain of the P2Y2R can interact with the actin-binding protein 
filamin A, a regulator of cytoskeletal rearrangements [101], and the C-terminal domain also 
has been shown to play a role in P2Y2R desensitization and internalization [127]. The 
P2Y2R also can regulate cell migration by activation of growth factor receptors [128], 
suggesting that a wide variety of cellular functions are likely mediated by P2Y2R 
interactions with integrins, growth factor receptors and cytoskeletal proteins well beyond the 
ability of the P2Y2R to mediate the Gq-dependent activation of PLC.
Current data indicate that P2Y2R expression is relatively low in neurons, but can be 
upregulated by the proinflammatory cytokine IL-1β [16]. Increased P2Y2R expression in 
neurons is likely to have neuroprotective effects, since P2Y2R activation promotes neurite 
outgrowth [129] and the α-secretase-dependent degradation of amyloid precursor protein 
(APP) to generate the non-amyloidogenic soluble APPα peptide, rather than the neurotoxic 
Aβ1-42 peptide associated with the pathophysiology of Alzheimer’s disease [16, 130]. In 
mouse primary microglial cells, the P2Y2R is upregulated by Aβ1-42, whereupon P2Y2R 
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activation increases the phagocytosis and degradation of neurotoxic forms of Aβ [24, 105, 
131]. Interestingly, studies have shown that P2Y2R expression is decreased in the parietal 
cortex of AD patients and this loss of P2Y2R expression was correlated with neuropathology 
and synapse loss [132]. These observations suggest that the loss of neuroprotective functions 
provided by the P2Y2R may contribute to disease pathogenesis in AD. Other potentially 
neuroprotective effects mediated by the P2Y2R include the regulation of synaptic 
transmission through the induction of intracellular calcium waves in astrocytic cells [133] 
and the upregulation of anti-apoptotic protein expression which promotes cell survival 
[134]. Activation of P2Y2Rs also has been shown to resensitize ionotropic P2X2 receptors in 
bladder sensory neurons [135] and vanilloid type 1 channels (TRPV1) in kidney sensory 
neurons [136]. The ability of the P2Y2R to activate metalloproteases, including TNF-α 
converting enzyme (TACE; or ADAM17) [16], may contribute to the AD phenotype 
through the production of TNFα, which has been shown to be upregulated in the brain and 
cerebrospinal fluid of AD patients [137, 138]. Taken together, the P2Y2R represents a 
promising target to promote neuroprotection in neurodegenerative diseases through the 
combined activation of P2Y2Rs in astrocytes, microglial cells and neurons.
The development of neurodegenerative diseases has been shown to be preceded by 
malfunctions in the cerebrovascular system, including decreased blood flow in the brain and 
breakdown of the blood-brain barrier (BBB) [139-141]. It is known that microvascular cells 
(i.e., endothelium and pericytes) affect neuronal functions by altering blood flow, BBB 
function and glucose/nutrient supply [140, 141]. These cells are also responsible for the 
clearance of toxic molecules and the secretion of trophic factors and extracellular matrix 
molecules required for proper neuronal functioning [140, 142]. It is, therefore, important to 
consider cerebrovascular function in relation to brain health.
Studies in various vasculature systems, including the cerebral microvasculature, have shown 
that intravenous or intraluminal application of ATP and/or UTP induces endothelium-
dependent relaxation of blood vessels and a decrease in blood pressure, which has been 
attributed to activation of the endothelial P2Y2R [82, 143-148]. Fewer in vivo studies have 
explored the effects of nucleotides on vascular permeability properties, although studies in 
frogs have shown that ATP increases the ion permeability of cerebral venules [149] and 
mesenteric microvascular permeability as measured by changes in hydraulic conductivity 
[150]. P2Y2Rs, which are expressed along with P2Y1,4,6 receptors in mouse aortic 
endothelium [151], increase blood flow through the release of NO [145]. In human 
mammary arteries, several P2Y receptor subtypes, including P2Y1,2,4,6 receptors, are 
thought to mediate vasodilatation by releasing NO, prostanoids or endothelium-derived 
hyperpolarizing factor [152]. In contrast, vascular smooth muscle cells express many P2X 
and P2Y receptors [153] that cause blood vessel constriction, which together help regulate 
vascular tone.
Cerebral microvessels are closely associated with several types of brain cells, including 
microglia and neuronal processes, and are encircled by the end feet of astrocytes, which are 
also thought to play a role in the regulation of local blood flow and barrier function [154]. 
Immunohistochemistry studies in rat brain slices indicate that the P2Y2R and the P2Y4R are 
strongly expressed in astrocytic end feet at the gliovascular interface and application of ATP 
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to freshly prepared brain slices triggers calcium waves in the astrocytic end feet that are 
propagated along the vessel wall, which the authors speculate is important for regulation of 
vascular permeability and tone [155]. Furthermore, Lewis et al., demonstrated in rat cerebral 
tissue that exogenous or extraluminal application of ATP evokes transient vasoconstriction 
of arterioles followed by sustained vasodilation, whereas UTP and UDP evoke sustained 
vasoconstriction [156]. Thus, the type of nucleotide and the route of administration 
(intravenous vs extraluminal) cause profound differences in vascular responses that are 
important to consider for drug development.
The P2Y4 Receptor
The human P2Y4R is activated by UTP (EC50 = 73 nM), but not by ATP, whereas the rat 
and mouse P2Y4Rs are activated equipotently by ATP and UTP, similar to the P2Y2R [26, 
89, 157-159]. Molecular docking studies indicate that the agonist binding site for the P2Y4R 
is similar to the P2Y2R with some variation in the second transmembrane domain and the 
second extracellular loop [89]. Activation of the P2Y4R has been shown to couple to Gq- 
and Go-dependent stimulation of PLCβ [26, 160] and the activation of Rho [161]. ATP has 
been shown to act as an antagonist at the human P2Y4R [160] and amino acid variations in 
the second extracellular loop and the N-terminal domain were found to play a role in 
determining whether ATP functions as an agonist or antagonist at mammalian P2Y4Rs 
[162]. In addition to UTP and ATP, P2Y4R agonists include UTPγS [163], 5-bromo-UTP 
[26], INS365, INS37217, and INS45973 [81-83]. However, all five of these compounds also 
display agonist activity at other P2Y receptors, especially the P2Y2R. To date, selective 
P2Y4R agonists have not been generated, although the compound 2’-azido-2’-deoxy-UTP 
has been shown to display slight selectivity for the P2Y4R over the P2Y2R (human P2Y4R: 
EC50 = 1 μM; human P2Y2R: EC50 = 5 μM) [89]. Similarly, definitive selective P2Y4R 
antagonists have not been generated, although the non-specific P2Y receptor inhibitor 
PPADS was shown to potently inhibit the UTP response at the human P2Y4R [160].
While little is known about the physiological or pathological effects of P2Y4R activation in 
the CNS, P2Y4R mRNA has been shown to be expressed in human brain [164] and in rat 
hippocampal pyramidal neurons where it has been suggested to have a presynaptic 
inhibitory role on the release of glutamate [21]. P2Y4R expression in astrocytes and 
microglial cells also has been extensively documented [14, 66, 157, 165], however, the 
physiological role of the receptor is unclear and may be complementary to the P2Y2R. 
P2Y4Rs are expressed in glial end feet in proximity to blood vessel walls, similar to P2Y2Rs 
[155], where their activation has been suggested to regulate BBB function, blood flow, 
metabolic trafficking and water homeostasis [155, 166]. The P2Y4R also has been shown to 
inhibit K+ currents in myocytes of rat cerebral arteries in a Rho-dependent manner [161].
The P2Y6 Receptor
The P2Y6R is activated preferentially by UDP (EC50 = 15 nM) and to a lesser extent by 
UTP [167]. UDPβS has been shown to be a more stable P2Y6R agonist, although this 
compound also displays agonist activity at the P2Y14R [163]. The synthetic compound 5-
iodo-UDP (MRS2693) has been shown to be a selective agonist for the human P2Y6R [168]. 
Interestingly, intraperitoneal injection of MRS2693 was shown to have a protective effect on 
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skeletal muscle in a mouse model of ischemia [169]. The compound 3-phenacyl-UDP 
(PSB0474) is a relatively selective agonist of the P2Y6R, as compared to the P2Y2R and the 
P2Y4R [90]. The diuridine triphosphate analog INS48823 also has been shown to be a 
potent and selective P2Y6R agonist (EC50 = 200 nM) [81] that, similar to INS365 and 
INS37217, can increase fluid flow across epithelial cell membranes [170]. Additionally, 
INS48823 has been shown to activate the NF-κB pathway in osteoclasts to increase cell 
survival [171]. Other P2Y6R agonists include α,β-methylene-UDP [91] and 5-bromo-UTP 
[167]. The P2Y6R activates PLCβ in a Gq-dependent manner [172], but has been shown to 
regulate pertussis toxin (PTX)-sensitive, voltage-gated Ca2+ currents in rat sympathetic 
neurons, suggesting the involvement of Gi/o [173]. The P2Y6R also can mediate G12/13-
dependent Rho activation, similar to the P2Y2R, although the involvement of integrins in 
this pathway has not been determined [174].
Diisothiocyanate derivatives of 1,2-diphenylethane (MRS2567) and 1,4-di-
(phenylthioureido)butane (MRS2578) have been demonstrated to be potent and selective 
antagonists at the rat and human P2Y6R (IC50 values ~ 40-130 nM), with no effect on 
responses induced by agonists of P2Y1, P2Y2, P2Y4 and P2Y11 receptors [175]. A 
derivative of 1,4-phenylendiisothiocyanate (MRS2575) also displays P2Y6R antagonist 
activity, but only at the human P2Y6R [175]. Among the non-selective P2YR antagonists, 
reactive blue 2 was shown to be more potent than PPADS and suramin at the P2Y6R [176].
P2Y6R mRNA is expressed throughout the human brain, but at highest levels in amygdala, 
cingulate gyrus, nucleus accumbens and putamen [164]. P2Y6R mRNA also has been 
identified in mouse superior cervical ganglion [177], rat dorsal-root ganglion neurons [65, 
67] and rat pyramidal hippocampal neurons [21]. Astrocytes in the cerebellum and cortex of 
rats also have P2Y6R activity [14, 178]. Similar to the P2Y2R, P2Y6R activation has been 
shown to increase the phagocytotic activity of microglia [179, 180], a response that was 
inhibited by the P2Y6R antagonist MRS2578. These observations suggest that a range of 
endogenous nucleotides and synthetic agonists/antagonists that act at different P2YR 
subtypes can be exploited therapeutically to induce neuroprotective responses, such as the 
microglia-dependent phagocytosis of neurotoxic forms of Aβ [24, 131]. Injury can enhance 
P2Y6R expression in rat astroglial cells [113] and P2Y6Rs in microglial cells are activated in 
response to bacterial lipopolysaccharide, implicating a role in neuroinflammation [66]. Thus, 
these data suggest that the P2Y6R, along with the other uridine nucleotide receptors, (i.e., 
P2Y2R and P2Y4R) can regulate protective mechanisms in the CNS under a variety of 
pathophysiological conditions. Other studies indicate that P2Y4 and P2Y6 receptors form 
homo- and hetero-oligomeric complexes in neuronal cells and dimeric P2Y4Rs and 
monomeric P2Y6Rs can partition into lipid rafts in synaptosomes [181], suggesting the 
possibility of complex P2YR interactions in the CNS.
The P2Y11 Receptor
The human P2Y11R is activated by ATP and leads to the activation of both PLC (EC50 for 
IP3 production = 65 µM) and adenylyl cyclase (EC50 for cAMP production = 17 µM), 
although ATPyS and 3’-O-(4-benzoyl)benzoyl adenosine 5’-triphosphate (BzATP) are more 
potent agonists than ATP [182]. UTP, in addition to ATP, has been shown to activate the 
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P2Y11R expressed in astrocytoma cells [183]. Interestingly, the ATP analogue 2-propylthio-
β,γ-dichloromethylene-D-ATP (AR-C67085), which had previously been shown to inhibit 
platelet aggregation through P2Y12R antagonism [184], was shown to be a potent P2Y11R 
agonist (EC50 for IP3 production = 9 µM; EC50 for cAMP production = 1.5 µM) [182]. The 
non-nucleotide phosphoric acid derivative 4,4'-(carbonylbis(imino-3,1-phenylene-
carbonylimino-3,1-(4-methyl-phenylene)carbony-limino))-bis1,3-xylene-α,α'-diphosphonic 
acid (NF546) is a selective P2Y11R agonist that has been shown to stimulate IL-8 release 
from human dendritic cells with similar potency as ATPγS [185]. Nicotinic adenine 
dinucleotide (NAD+) and nicotinic adenine dinucleotide phosphate (NADP+) have been 
shown to be agonists of P2Y11Rs expressed in human granulocytes and astrocytoma cells, 
respectively [186, 187]. The P2Y11R can regulate both Gs-dependent activation of adenylyl 
cyclase and Gq-dependent activation of PLC [183, 188-190]. P2Y11Rs expressed in 
astrocytoma cells mediate UTP-induced PLC activation by a pertussis toxin (PTX)-sensitive 
mechanism and ATP-induced PLC activation by a PTX-insensitive mechanism, indicating 
coupling to PLC via both Go and Gq proteins [183]. The coupling of the P2Y11R to multiple 
G proteins may be due to the ability of the P2Y11R to form heterodimers with other P2YRs, 
such as the P2Y1R [191].
The nucleotide analogue AMPaS (5’-AMPS) has been shown to be an effective P2Y11R 
antagonist [182, 192]. Suramin was a more potent antagonist of the P2Y11R than reactive 
blue 2, whereas PPADS was completely inactive [182], and the antagonist potency and 
selectivity of suramin at the P2Y11R over P2Y1, P2Y2 and several ionotropic P2X receptors 
could be further increased by substitution of methyl groups in suramin with fluorine [193]. 
The resulting suramin derivative, 8,8'-(carbonylbis(imino-3,1-phenylene-carbonylimino(4-
fluoro-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic acid (NF157), was 
shown to prevent NAD+-induced human granulocyte migration through P2Y11R antagonism 
[187]. Another non-nucleotide antagonist of the P2Y11R, 4,4’-(carbonylbis(imino-3,1-(4-
methyl-phenylene)carbonylimino))bis-naphthalene-2,6-disulfonic acid (NF340), showed 
relative selectivity at the P2Y11R over the P2Y1, P2Y2, P2Y4, P2Y6, P2Y12, and P2X1-3 
receptors [185].
Although the rodent P2Y11R gene has not been cloned, studies have suggested that P2Y11R 
mRNA is expressed in the nucleus accumbens, parahippocampal gyrus, putamen and 
striatum of rats [1]. Additional studies using human P2Y11R primers for PCR and anti-
human P2Y11R antibodies have localized the P2Y11R to rat hippocampal pyramidal neurons 
and Purkinje cells in the adult rat cerebellum [21, 194]. Since a rodent P2Y11R gene has not 
been cloned, it is difficult to conclude that rodents express a P2Y11R. In human neutrophils, 
P2Y11R activation has been shown to delay pathogen- or inflammatory mediator-induced 
apoptosis by a cAMP-dependent mechanism, suggesting a protective role for the P2Y11R 
under neuroinflammatory conditions [190]. Similarly, in human monocytes, P2Y11R 
activation inhibits toll-like receptor signaling by increasing cAMP production [189]. 
P2Y11Rs in monocyte-derived dendritic cells also have been shown to regulate 
thrombospondin-1 secretion and inhibition of lipopolysaccharide-stimulated interleukin-12 
release [185]. Thus, P2Y11Rs represent a promising therapeutic target for the treatment of 
neuroinflammatory diseases.
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The P2Y12 Receptor
The P2Y12 receptor is activated by the endogenous agonist ADP (EC50 = 60 nM), whereas 
2-MeS-ATP and 2-MeS-ADP are more potent agonists [195]. Activation of the P2Y12R 
couples to both Gi protein [196, 197] and Go protein [196, 198]. Vesicle reconstitution of the 
P2Y12R with different G proteins demonstrated that the P2Y12R couples more effectively to 
Gαi2 than to Gαi1 and Gαi3, but does not couple to Gαo or Gαq proteins [199], suggesting 
that Go coupling may be due to formation of heteromeric receptors with other P2YRs.
A wide variety of P2Y12R antagonists have been described, due to the central role of the 
P2Y12R in the initiation of platelet aggregation [200-203]. The thienopyridine-ADP family 
of P2Y12R antagonists include clopidogrel (methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydro-
thieno[3,2-c]pyridine-5(4H)acetate sulfate; Plavix), ticlopidine (5-[(2-
chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3, 2-c] pyridine hydrochloride; Ticlid) and 
prasugrel (5-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride; LY640 315; CS-747; Effient) 
[204, 205]. Ticlopidine was discovered over 30 years ago [204, 206] and the anti-platelet 
aggregation properties of clopidogrel were found decades before the cloning and 
identification of its endogenous target, the P2Y12R [41, 207]. Following conversion to their 
respective active thiol derivatives in the liver, these orally active antagonists irreversibly 
bind to cysteine residues in the P2Y12R and prevent ADP-induced platelet aggregation. In 
the case of clopidogrel, binding to the receptor disrupts the formation of lipid raft-associated 
P2Y12R oligomers, the speculated functional form of the receptor, suggesting a possible 
mechanism of antagonism [208]. Therapeutic use of Plavix, Ticlid and Effient has been 
FDA-approved for prevention of a number of cardiovascular pathologies, including 
myocardial infarction, stroke, and peripheral artery disease [204].
Observations that ATP can act as a P2Y12R antagonist [209] led to investigations of the 
antagonist activity of stable ATP analogs [41]. The ATP analog family of competitive 
P2Y12R antagonists includes the AR compounds AR-C67085, AR-C66096 (2-
(propylthio)adenosine-5'-O-(β,γ-di-fluoromethylene)triphosphate), AR-C69931 (Cangrelor; 
N6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid) [184, 210, 211] and 
the orally active non-phosphorylated AstraZeneca compound AZD6140 (Ticagrelor; 
Brillinta; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-
(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-
cyclopentanediol) [212]. Similar to AZD6140, the orally active drug PRT-060128 
(Elinogrel; N-[(5-chlorothiophen-2-yl)sulfonyl]-N’-(4-[6-fluoro-7-(methylamino)-2, 4-
dioxo-1, 4-dihydroquinazolin-3(2H)-yl]phenyl)urea) was shown to be an effective reversible 
antagonist of P2Y12R [213]. While Elinogrel failed to make it out of Phase II clinical trials, 
Brillinta (AZD6140) has been approved by the FDA for prevention of adverse 
cardiovascular events. Additional P2Y12R antagonists include the tricyclic 
benzothiazolo[2,3-c]thiadiazine derivative CT50547 [214], BX-667 ((S)-4-((4-[1-
(ethoxycarbonyl)-1-methylethoxy]-7-methyl-2-quinolyl)carbamoyl)-5-[4-(ethoxycarbonyl) 
piperazin-1-yl]-5-oxopentanoic acid) [215], MRS2395 (2,2-dimethyl-propionic acid 3-(2-
chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester) [216], 
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and the reactive blue 2 analog PSB0739 (1-amino-4-[4-phenylamino-3-
sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) [217].
Besides in platelets, the P2Y12R is highly expressed in astrocytes [207, 218], including in 
the rat nucleus accumbens of the cortex and cerebellum [14, 113, 219] and in rat 
hippocampal pyramidal neurons [21]. P2Y12Rs have also been shown to be expressed in rat 
brain microglial cells where they are suggested to regulate microglial cell migration to 
neurons in response to injury [220] and directional migration of glial cell processes to axons 
during premyelination [221]. Accordingly, transgenic mice with selective deletion of the 
P2Y12R show reduced directional microglial branch extension in vivo, as compared to 
control mice who exhibited significantly less P2Y12R expression in activated microglia than 
in resting microglia, suggesting a role for the P2Y12R in early stages of CNS injury and a 
potential therapeutic pathway that may be exploited for treatment of neurodegenerative 
diseases [222]. However, another study indicated that expression of the P2Y12R in the CNS 
is limited to oligodendrocytes [221].
The P2Y12R has been shown to increase the proliferation of glioma cells by the Gαi-
dependent activation of RhoA, ROCK and PKCζ, independent of ERK1/2 activation [197], 
although P2Y12R-mediated proliferation of Chinese hamster ovary cells was linked to 
activation of PI3K/Akt and ERK1/2, whereas a separate PTX-insensitive pathway leading to 
RhoA and ROCK activation was found to regulate actin cytoskeletal reorganization [196]. 
Interestingly, the P2Y12R has been shown to play a role in glioma progression and 
malignancy where antagonism of the receptor with clopidogrel retarded the growth of 
NTPDase2-overexpressing gliomas in rats [223]. The P2Y12R is also expressed in mouse 
dendritic cells, where it mediates the Go-dependent macropinocytosis of antigens [198]. 
Reconstitution of the P2Y12R with different G proteins indicates that the P2Y12R 
preferentially couples to Gαi2-dependent inhibition of adenylyl cyclase and the activation of 
PI3K, Akt, Rap1b and potassium channels, in comparison to Gαi1 and Gαi3, and does not 
couple to Gαo or Gαq proteins [199].
The P2Y13 Receptor
The P2Y13R is activated by ADP with an EC50 = 60 nM [224], and 2-MeS-ADP has been 
shown to be a potent agonist [225]. The P2Y13R is activated more potently by 2-MeS-ADP, 
adenosine 5'-O-2-(thio)diphosphate (ADPβS) and 2-MeS-ATP than by the endogenous 
agonist ADP [224]. BzATP also has been shown to be a P2Y13R agonist in rat cerebellar 
astrocytes [226]. Similar to the ADP-activated P2Y12R, the P2Y13R couples to Gi-mediated 
inhibition of adenylyl cyclase [224], but can also couple to Gs-dependent activation of 
adenylyl cyclase at high agonist concentrations [227]. The P2Y13R, like other P2YRs, can 
activate RhoA and ROCK [228, 229], suggesting that it will contribute to cytoskeletal 
rearrangements induced by adenine nucleotides in cells of the CNS.
The P2Y12R antagonists AR-C69931 and AR-C67085 are potent non-competitive 
antagonists of the P2Y13R with IC50‘s = 4 nM and 1 nM, respectively, whereas diadenosine 
tetraphosphate, reactive blue 2, suramin and PPADS also antagonized the effects of ADP at 
the P2Y13R [227]. Derivatives of PPADS, including the 2-chloro-5-nitro (MRS2211) and 4-
chloro-3-nitro (MRS2603) analogues, were significantly more potent P2Y13R antagonists 
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than PPADS, whereas MRS2211 showed significant specificity for antagonism of the 
P2Y13R, as compared to the P2Y1 and P2Y12 receptors [230]. MRS2211 was also shown to 
inhibit BzATP-induced increases in the intracellular calcium concentration in cerebellar 
astrocytes through antagonism of the P2Y13R [226].
P2Y13Rs are expressed in astrocytes and glutamatergic neurons and have been shown, along 
with P2Y1 and P2Y12 receptors, to enhance Na+ and Cl−-dependent glycine transport in the 
synaptic cleft [231]. The P2Y13R also has been suggested to enhance cell survival by 
increasing the PI3K/Akt-dependent translocation of the glycogen synthase kinase-3 substrate 
β-catenin to the nucleus to promote the expression of cell survival genes [232]. Thus, the 
P2Y13R fits the general profile of the P2YR family with respect to their likely roles in the 
regulation of protective or reparative processes in the CNS.
The P2Y14 Receptor
The P2Y14R is unique among the P2YR family in its ability to be activated by UDP-glucose 
(EC50 = 80 nM), UDP-galactose (EC50 = 125 nM), UDP-glucuronic acid (EC50 = 370 nM) 
and UDP-N-acetylglucosamine (EC50 = 710 nM), but not by adenine or uridine nucleotides 
(e.g., ATP, ADP, UTP and UDP) [225, 233, 234]. The 2-thio-modified UDP-glucose analog 
MRS2690 (diphosphoric acid 1-alpha-d-glucopyranosyl ester 2-[(2-thio)uridin-5"-yl] ester) 
is a potent P2Y14R agonist [235]. Modifications in the uracil moieties of P2Y14R agonists 
abolish activity [236]. The P2Y14R has been shown to couple to Gi/o protein activation 
[235].
The effects of P2Y14R activation and its therapeutic relevance in the treatment of CNS 
disorders are largely unknown. The P2Y14R is expressed in human astrocytes [237] and in 
rat cortical and cerebellar astrocytes [14, 219]. P2Y14R expression was increased in rat 
primary microglial cells in response to bacterial lipopolysaccharide [66], suggesting a role 
during neuroinflammation. P2Y14Rs expressed in immature dendritic cells have been 
suggested to have an immunoregulatory function [23, 238]. P2Y14R activation also can 
increase the production of chemokines and cytokines involved in the recruitment of 
neutrophils, including IL-8, macrophage inflammatory protein-2 and keratinocyte-derived 
cytokine [239], and the P2Y14R has been shown to play a role in muscle contractility in rats 
and gastric function in mice [240].
CONSIDERATIONS FOR THE THERAPEUTIC USE OF P2Y RECEPTOR 
AGONISTS AND ANTAGONISTS
Blood-Brain Barrier
P2Y receptors in the CNS, particularly in the brain, represent promising targets in the 
treatment of neuroinflammatory and neurodegenerative diseases and there is a critical need 
for the development of more stable and selective P2Y receptor agonists/antagonists. Of 
greatest need are drugs that can cross the blood-brain barrier (BBB), which represents a 
major obstacle to the efficient delivery into the brain of drugs designed to mimic the 
negatively-charged structure of nucleotides that is known to be critical for agonist binding to 
P2YRs. The BBB is composed of cerebral endothelial cells, pericytes and astrocytes that 
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regulate the flow of proteins and macromolecules into the CNS [241]. Potential therapies 
involving P2YR agonists and antagonists that target the CNS must consider modes of 
transport across the BBB, which for small polar molecules such as nucleotides likely can 
occur via plasma membrane transport proteins, receptor- or adsorptive-mediated 
transcytosis, or passage through endothelial cell tight junctions [241]. Studies have shown 
that P2Y receptors and P1 adenosine receptors are able to modulate the permeability of the 
blood brain barrier [149, 242]. Remarkably, treatment of murine models with the FDA 
approved A2A adenosine receptor agonist regadenoson (Lexiscan) can increase BBB 
permeability to intravenously injected macromolecules, including anti-β-amyloid antibody, 
through a mechanism involving alterations in endothelial cell tight junctions [243]. Recent 
studies, including unpublished studies in our lab [Erb et al., submitted manuscript], indicate 
that activation of P2Y2Rs in vascular endothelium can increase the transendothelial 
permeability of leukocytes [109, 244, 245], suggesting that P2Y2R activation in brain 
microvessels that comprise the BBB may be a novel target for increasing drug delivery to 
the brain. It seems likely that any P2Y receptor agonists/antagonists targeted to the CNS 
must possess properties that are conducive to passage across the BBB or these compounds 
will have to be administered along with modulators of barrier function.
P2Y Receptor Interactions
Another important consideration in the targeting of P2Y receptors for therapeutic treatments 
is whether the functions being affected are a product of homomeric P2YR activation or are 
regulated by heteromeric interactions between different P2YR subtypes. For example, in 
vitro experiments have suggested that the P2Y11R can form a hetero-oligomeric complex 
with the P2Y1R which is internalized upon activation with ATP or 2-MeS-ADP and has a 
distinct agonist/antagonist profile that differs from both P2Y1R and P2Y11R [246]. 
Heteromeric interactions between P2Y receptors and P1 adenosine receptors also have been 
reported. The P2Y1R has been shown to form functional hetero-oligomers with the A1 
receptor (A1R) both in vitro [247] and in the rat cortex, hippocampus, and cerebellum [248, 
249]. While the physiological contributions of this heteromeric P2Y1:A1 receptor are 
unknown, it has been demonstrated that addition of the P2Y1R agonist 2-MeS-ADP 
decreases A1R-mediated functional responses [250], whereas addition of the A1R agonist 
N6-cyclohexyladenosine enhances the 2-MeS-ADP-induced G protein coupling to P2Y1Rs 
[248]. In addition, multiple homomeric P2Y and P2X receptor subtypes in a single cell type 
are likely to be activated simultaneously by the same nucleoside triphosphate (i.e., ATP or 
UTP) or breakdown products (i.e., ADP or UDP) and, therefore, may interact downstream of 
receptor activation via overlapping signal transduction pathways. Considering that multiple 
cell types that comprise the brain are likely to have a cell-specific complement of P2 
receptor subtypes that are differentially expressed under a variety of physiological and 
pathophysiological conditions, it is very difficult to assess the contributions in vivo of 
individual P2Y receptor subtypes in specific cell types to neurological responses to released 
nucleotides in the brain. Although the deletion of specific P2YR subtypes in mice has helped 
reveal the physiological role of some P2YR subtypes, the use of these mouse models to 
evaluate P2YR interactions is in its infancy and more information is available from in vitro 
studies using receptor antagonists. For example, a recent study has shown that ADP 
increases axonal elongation in cultured rat hippocampal neurons [72]. However, ADP can 
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activate multiple P2Y receptors in neurons, including the P2Y1R and the P2Y13R. Through 
the use of selective P2YR antagonists (MRS2179 for the P2Y1R and MRS2211 for the 
P2Y13R) and the suppression of P2Y1R or P2Y13R expression in neurons with siRNA, it 
was shown that axonal growth in response to ADP was coordinately regulated by both 
P2Y1R and P2Y13R activation and their opposing effects on the activation of adenylate 
cyclase 5. Whereas activation of adenylyl cyclase 5 by the P2Y1R stimulated axonal 
elongation likely via Gq-dependent PI3K/Akt activation, P2Y13R-mediated Gi activation 
inhibited adenylate cyclase 5 activity and axonal elongation. Furthermore, antagonism of the 
P2X7R also increased axonal elongation by modulating adenylate cyclase 5 activity [72]. 
The complexity of axonal elongation in response to ATP or ADP, as demonstrated by this 
study, accurately depicts the challenges of targeting P2Y receptors for therapy. 
Alternatively, this complexity could be advantageous in that a desired physiological 
response (e.g., axonal growth) can be targeted through activation or inhibition of individual 
P2YR subtypes.
Indirect interactions between the Gq protein-coupled P2Y2 receptor and the ionotropic P2X7 
receptor have been suggested to mediate neuroprotective responses in neuroinflammatory 
diseases, such as AD [35, 105, 251]. Under inflammatory conditions, such as those found in 
AD [114-115], ATP is released from apoptotic cells into the extracellular milieu where it 
activates the P2X7R to induce the processing and release of the proinflammatory cytokine 
IL-1β [4, 252, 253]. In response to IL-1β, P2Y2R expression has been shown to be 
upregulated in rat [16] and mouse [Weisman et al., submitted manuscript] primary cortical 
neurons through a NF-κB-dependent mechanism [16, 116]. As described above, activation 
of the P2Y2R has been shown to induce neuroprotective responses, such as stimulation of 
the non-amyloidogenic processing of amyloid precursor protein to generate soluble APPa, 
rather than the neurotoxic beta-amyloid peptide [130], and the stimulation of neurite 
outgrowth [254; Weisman et al., submitted manuscript]. Additionally, P2Y2R activation in 
microglial cells has been shown to increase uptake and degradation of neurotoxic Aβ1-42 
[24]. IL-1β also has been shown to be elevated in the brains of AD patients [114, 115] and 
the P2X7R is upregulated around Aβ plaques in an AD mouse model [255]. These findings 
suggest that a cascade of events starting with tissue damage can induce the activation of 
P2X7Rs and IL-1β receptors to increase the expression of P2Y2Rs, thereby counteracting a 
neurodegenerative response (i.e., IL-1β and ATP release) by enhancing a neuroprotective 
pathway (i.e., P2Y2R-mediated neurite extension and neurotoxic Aβ elimination).
CONCLUSION
Recent research has demonstrated the existence of 8 P2Y receptor subtypes (i.e., 
P2Y1,2,4,6,11-14) that are expressed in cells of the CNS (e.g., neurons, astrocytes, microglia 
and endothelial cells). When ATP, UTP and other nucleotides are released from cells in the 
CNS under a variety of conditions, including neurotransmission, apoptosis, inflammation 
and cell damage, the activation of these P2Y receptor subtypes stimulates intracellular signal 
transduction pathways that regulate physiological and pathological responses, including 
neurite outgrowth, glial cell migration and proliferation, glial cell-mediated phagocytosis, 
amyloid precursor protein processing, gene expression, cytokine release and diapedesis. 
These P2Y receptor-mediated responses to extracellular nucleotides are induced by the 
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direct or indirect activation of G proteins (e.g., Gs, Gi, Gq, and G12/13) and the modulation of 
intracellular protein activities, including adenylyl cyclase, phospholipase C, small GTPases, 
matrix metalloproteases, integrins, growth factor receptors and protein kinases. Current data 
suggest that P2Y receptor activation in the CNS, particularly in the brain, can serve a 
neuroprotective role. Therefore, novel agonists and antagonists are being actively pursued 
that are relatively selective for single P2Y receptor subtypes and may potentially have a 
wide variety of therapeutic applications in the treatment of pathologies of the CNS.
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ABBREVIATIONS
2-MeS-ADP 2-Methylthio-ADP
2-MeS-ATP 2-Methylthio-ATP
AD Alzheimer’s disease
ADP Adenosine 5’-diphosphate
ATP Adenosine 5’-triphosphate
APP Amyloid precursor protein
BBB Blood-brain barrier
cAMP Cyclic adenosine 3-,5’-monophosphate
CNS Central nervous system
GTP Guanosine 5’-triphosphate
IL-1β Interleukin-1β
IP3 Inositol 1,4,5-trisphosphate
P2YR P2Y receptor
PCR Polymerase chain reaction
PKC Protein kinase C
PLC Phospholipase C
PPADS Pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid
UDP Uridine 5’-diphosphate
UTP Uridine 5’-triphosphate
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Table 1
P2Y Receptor Agonists and Antagonists
Receptor Agonists Antagonists Potential Therapeutic Pathways
P2Y1
Endogenous: ADP
Synthetic: 2-MeS-ADP, MRS 2365,
ATP-α-B derivatives, (Ap5(γ-B)A),
β,γ-Me-ATP, Di-(2-MeS)-adenosine 5',5"-
P1,P4,α,β-methylene-tetraphosphate,
2-MeS-β,γ-CCl2-ATP
PPADS, Suramin,
Reactive blue 2, ATPαS,
β,γ-methylene-ATP,
A3P5PS, A3P5P, A2P5P, 
MRS2179,
MRS2500, MRS2279
Antagonists can prevent
cytokine/chemokine-induced damage
following ischemia in mice, agonists can
induce axonal elongation in neurons and
modulation of pain sensation, antagonists
can reduce anxiolytic behavior in rats
P2Y2
Endogenous: ATP or UTP
Synthetic: UTPγS, Ap4A,
INS365 (Diquafosol), INS37217 (Denusofol),
INS45973, 2'-amino-2'-deoxy-UTP,
6-nitro-UTP, UTPαS, 2'-deoxy-UTPaS,
2-thio-UTP, MRS2768, PSB1114
PPADS, Suramin,
Reactive blue 2, PSB716
Agonists can increase the migration of glial
cells through P2Y2R/integrin interactions,
proliferation of glial cells, non-
amyloidogenic APP processing in neurons,
and the uptake and degradation of
neurotoxic forms of Aβ1-42 by microglial cells
P2Y4
Endogenous: UTP (humans), UTP or ATP 
(mice,
rats)
Synthetic: UTPγS, 5-bromo-UTP,
INS365 (Diquafosol), INS37217 (Denusofol), 
2’-
azido-2’-deoxy-UTP
PPADS, Reactive blue 2
P2Y4R activation can inhibit presynaptic
glutamate release, modulate blood-brain
barrier function, and inhibit K+ currents in
rat myocytes
P2Y6
Endogenous: UDP
Synthetic: UDPpS, MRS2693, PSB0474,
INS48823, α,β-methylene-UDP, 5-bromo-UTP
PPADS, Suramin,
Reactive blue 2, MRS2567,
MRS2578, MRS2575
P2Y6R activation can increase phagocytic
activity of microglia and regulate repair
mechanisms in response to CNS injury
P2Y11
Endogenous: ATP
Synthetic: ATPγS, BzATP, UTP, AR-C67085,
NF546, NAD+, NADP+
Suramin, Reactive blue 2, 
AMPαS,
NF157, NF340
P2Y11R activation delays pathogen- or
inflammation-induced apoptosis in
neutrophils, inhibits TLR signaling and
modulates cytokine release
P2Y12 Endogenous: ADPSynthetic: 2-MeS-ATP, 2-MeS-ADP
Clopidogrel (Plavix), 
Ticlopidine
(Ticlid), Prasugrel (Effient),
Ticagrelor (Brillinta), 
Elinogrel, AR-
C67085, AR-C66096,
AR-C69931, CT50547, 
BX-667,
MRS2395, PSB0739
P2Y12R antagonists are in widespread
clinical use as inhibitors of platelet
aggregation, and P2Y12R activation can
regulate glial cell migration and increase cell
proliferation
P2Y13
Endogenous: ADP
Synthetic: 2-MeS-ADP,
2-MeS-ATP, ADPβS, BzATP
PPADS, Suramin,
Reactive blue 2, Ap4A,
AR-C69931, AR-C67085, 
MRS2211,
MRS2603
P2Y13R activation enhances glycine
transport in the synaptic cleft, and promotes
cell survival through a PI3K/Akt-dependent
mechanism
P2Y14
Endogenous: UDP-glucose
Other: UDP-galactose, UDP-glucuronic acid,
UDP-N-acetylglucosamine
Synthetic: MRS2690
P2Y14R activation can modulate
inflammatory responses through chemokine
and cytokine production, and may play a
role in muscle contraction
The EC50 values for endogenous agonists, the chemical names of agonists and antagonists and the associated references are given in the main text.
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